Sales Internship

Sales Internship

Innovative and ambitious company within personal health technology seeks a sales intern to support our company growth.

This is a full-time, unpaid internship in Copenhagen for a minimum five months (starting date can be discussed) and should be part of the applicant’s education

Key responsibilities 

  • Assist in lead management and sales processes
  • Support sales force in Denmark and UK
  • Customer and market segment screening and analysis
  • Make product demonstrations for customers and partners
  • Create product and online/social media content
  • Coordinate our participation at international conferences and exhibitions
  • Update and maintain our CRM system

What we offer

We offer you a fantastic opportunity to join a young company, where you truly have the ability to make an impact and help shape the future in an exciting field. Personal health technology and digital health are booming markets worldwide. You will have the opportunity to join us on our quest to provide innovative solutions for disease management and treatment support and thereby reduce the burden of mental illness in society. Our informal, fast-paced environment will give you great opportunities to grow professionally and personally.

Desired skills and expertise 

  • Taking a degree in Engineering, Business, Communications, psychology, public health, or other relevant programme.
  • Skilled knowledge of MS Office (Excel, Word, PowerPoint) and preferably also of CRM systems.
  • Excellent English skills. Other major languages would be valued positively.
  • Good communication skills – orally as well as in writing.
  • Able to work independently with tasks – yet with good interpersonal skills.
  • Strong interest in digital health, health technologies, and/or mental health

Please note, that this is a full-time unpaid internship in Copenhagen, Vesterbro, for a minimum of five months (start date August or September 2022, but the exact date can be discussed).

Contact 

For questions regarding this position contact Josefine Zacher at zacher@monsenso.com

This internship is only available for students enrolled at a Danish university.

To apply for this internship, please submit a Cover letter and your CV to jobs@monsenso.com

Monsenso moves into a new disorder area with a new project covering Multiple Sclerosis

Monsenso moves into a new disorder area with a new project covering Multiple Sclerosis

Monsenso, leading provider of digital solutions for mental health, moves into a new disorder area with a project covering Multiple Sclerosis (MS). The project is part of the HedaX research project and is conducted jointly with the Danish Multiple Sclerosis Society

The aim of the project, led by Lasse Skovgaard from the Danish Multiple Sclerosis Society, is to explore whether data-driven insight from daily self-assessments can empower users to better manage their disease.

In Denmark, approximately 17.200 people have Multiple Sclerosis (MS), and worldwide there are 2.1 million people diagnosed with MS. MS is an autoimmune disease in which the body’s immune system (autoantibodies) begins to attack and destroy the body’s own nerve cells. MS is a progressive disorder that can affect different places in the central nervous system, why symptoms and disabilities are manifold. Due to the broad heterogeneity among the MS patients’ disease courses, it is difficult to personalise a treatment course for better outcomes.

The aim of the study, therefore, is to validate whether data-driven insight from daily self-assessments can empower users and serve as a tool for individual disease management.

Study participants will be provided with the Monsenso app to assess daily self-assessments of symptoms, lifestyle measures and quality of life. Through visualisation of the historical data, the users can gain better insight into the behaviours that trigger their symptoms, thereby empowering them to better manage their disease.

The project is part of the HedaX research project, funded by the Innovation Fund Denmark, which involves ten public and private partners working together to develop a digital platform to ensure health data is securely captured and shared between individuals, healthcare professionals and researchers. The HedaX-project initially covered cancer and bipolar patients but will now be extended to cover MS patients.

‘’The project with Monsenso offers an opportunity to work closely with a patient organisation and determine whether patients can manage their disease better through the use of a state-of-the-art patient-centred app. The Danish Multiple Sclerosis Society was chosen as a partner because they have a clear ambitious digital strategy’’ says Troels Bierman Mortensen, CEO of DataFair and Project Manager for the HedaX project.

“Multiple Sclerosis is a serious and disabling disease. We are therefore pleased if the Monsenso solution can help to improve future treatments,” says Thomas Lethenborg, CEO of Monsenso.

About the Danish Multiple Sclerosis Society

The Danish Multiple Sclerosis Society is a nationwide organisation with 48 local branches throughout the country and the Faroe Islands and over 60 years of experience in making a difference by leading the way in research, patient support and providing information on Multiple Sclerosis. The organisation counts more than 60,000 members and donors – including 12,000 members with MS which corresponds to 80 percent of all Danish patients with MS.

About Monsenso

Monsenso is an innovative technology company offering a digital health solution. Our mission is to help provide better mental health to more people at lower costs. Our solution helps optimise the treatment of mental disorders and gives a detailed overview of an individual’s mental health through the collection of outcome, adherence and behavioural data. It connects individuals, carers and health care providers to enable personalised treatment, remote care and early intervention. Based on continuous research and development, our team is committed to developing solutions that fit seamlessly into the lives of individuals, increase their quality of life and improve the efficacy of mental health treatment. To learn more visit www.monsenso.com

To read the Danish version, click here

For additional information contact:

Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Monsenso signs contract with the Norwegian University of Science & Technology

Monsenso signs contract with the Norwegian University of Science & Technology

Monsenso has signed a contract with the Norwegian University of Science & Technology to use Monsenso’s digital health solution to collect sensor data in a research project aiming at improving relapse prevention with substance use disorders.

The research study aims to improve the prediction of relapse using mobile sensing to identify a digital phenotype approach to relapse prevention. The research project is led by Anders Lauvsnes, Department of Mental Health, Faculty of Medicine and Health Sciences, at the Norwegian University of Science & Technology and covers up to 100 research participants with substance use disorders.

Mobile sensing, the use of passive data generated by personal electronic devices such as smartphones and wearables to measure human functioning, has generated considerable research interest over the past years. Particularly in the field of mental health, where the collection of continuous and objective data can lead to clinically useful biomarkers to support the prevention, early intervention, and treatment of a variety of conditions, including addiction.

“Addiction and substance use disorders are major health challenges worldwide, and relapse is a core component of addictive disorders. The dynamics surrounding relapse, and particularly the immediate period leading up to it, are only partially understood, due in large part to the difficulty of collecting reliable and sufficient data from this narrow period,” says Anders Lauvsnes. “Mobile sensing offers the opportunity to identify predictive patterns of relapse by accurately mapping behaviour. Together with data on symptoms worsening, it can help us identify a digital phenotype for relapse prevention”.

The Monsenso digital solution will be used to remotely monitor study participants, collecting sensor data from mobile phones along with sensor data from wearables (Whitings). After completion of the data collection, the data will be analysed along with neurocognitive measures using machine learning to predict imminent relapse to substance use and describe individual and temporal variability in risk.

“We are very excited to contribute to this project of creating a digital phenotype to help reduce relapse,” said Thomas Lethenborg, CEO of Monsenso. “Mobile sensing does indeed offer a data-driven method to improve condition monitoring for actionable outcomes, such as early signs of relapse, thereby ensuring the right individuals receive the right treatment at the right time”.

About Monsenso digital health solution:
The Monsenso solution is a clinically validated, CE Class I Marked digital solution classified as a Medical Device, consisting of a smartphone app for patients and a clinical web portal for healthcare providers that are widely used in the prevention and treatment of common behavioural disorders such as depression and anxiety. It can also be configured to prevent and treat severe mental illnesses such as depression, bipolar disorder, borderline personality disorder, PTSD, and schizophrenia. It is currently being used by over 1,000 patients across the globe and is highly valued by patients and healthcare providers.

For additional information contact:
Bettina van Wylich-Muxoll
Chief Marketing Officer
marketing@monsenso.com
Monsenso

Patient Voice in RWE: generating evidence that will impact payer and HTA decision-making

Patient Voice in RWE: generating evidence that will impact payer and HTA decision-making

With the rise of patient-centered medicine and accelerated approvals, health technology assessment (HTA) bodies and payers are looking to real-world evidence (RWE) to strengthen evidence packages and reduce uncertainties at the time of launch.

Increasingly, stakeholders are recognizing the importance of RWE that incorporates patients’ real-world experiences in understanding what treatments work, and for whom, in clinical practice.

Real-world evidence is generated through applying data science to real-world data (RWD), or data “relating to patient health status or the delivery of healthcare routinely collected from EHRs, claims, registries, patient-reported outcomes, devices/applications, etc.” Decision-makers are exploring how this evidence can supplement clinical trials and provide additional context on the effectiveness of therapies.

There is some overlap between patient experience data, which provides information about a patient’s experience with a disease or condition, and real-world data (RWD), however, they are not one and the same. For example, patient-reported outcomes (PROs) collected in an electronic health record (EHR) would be considered both RWD and patient experience data, however, lab test results in the medical record would be considered only RWD. As personalized medicine continues to gain traction, decision-makers like ICER, FDA, NPC, EMA, EUNetHTA, and EHDEN are calling for patients’ voices to be included in the drug development and assessment process. Such information – direct input from patients on how they feel and function is often lacking from RWD sources, and FDA and EMA identified such missing data as problematic for interpretation.

We spoke with Ashley Jaksa MPH, Scientific Partnerships Lead, Aetion and Chung Yen Looi, DPhil Partnerships Director, Monsenso, about the evolving landscape of patient experience data and how biopharma organizations can incorporate the patient voice into their RWD and RWE programs.

Q: Ashley, can you tell our readers a little more about what Aetion does? 

AJ: Aetion is a healthcare technology company that uses routinely collected health care data to generate RWE on the safety and effectiveness of medical treatments and technologies. We were founded by Harvard epidemiologists to develop a way to conduct scalable and transparent RWD analyses at the highest level of scientific rigour. Our RWE analytics platform helps biopharma organizations, regulators, HTAs, payers, and other researchers generate RWE to inform decisions on the safety, effectiveness, and value of medical interventions across the product lifecycle. Our platform is data fluent, meaning it can analyze almost any type of RWD, and we often work with our customers and partners to identify the most fit-for-purpose data set for their research question.

Q: Why is the patient experience important for biopharma to understand, and where in the drug development lifecycle is it most important to integrate patients’ voices? 

CL: I think we can all agree that pharma and its stakeholders want to develop safe and effective drugs and bring them to market, to improve patients’ lives. As such, asking patients directly about how a drug impacts their lives is critical. Without the patient voice, we will never know how patients experience therapies in the real world, and how medical interventions could make a meaningful difference to their lives. Capturing and incorporating the patient voice across the product lifecycle can help biopharma companies to better understand the real-world impact of their drug, treatment responders, and meaningful endpoints based on a wider, representative population, in a quick and cost-effective way. 

AJ: Similar to RWE, patient experience data is important in almost all stages of the product lifecycle—not just as a post-marketing exercise. For example, understanding the treatment pathways and patient experiences on first-line therapies can help shape what comparators and outcomes should be captured in future randomized controlled trials to differentiate the drug in the market.

Q: How can incorporating the patient voice improve market access?

CL: Patient voice is a powerful way to demonstrate the impact of a drug on patients’ quality of life to payers and HTA bodies, particularly for cost-effectiveness evaluations. Some biopharma organizations have used PRO measures on daily functioning and health-related quality of life as their primary and secondary endpoints in clinical and real-world studies, while others have directly linked PROs to their drug reimbursement contracts. Patient voice contributions can help biopharma companies differentiate their product from similar drugs for coverage, especially for payers who are tying reimbursement to the value to patients based on outcomes and have longer-term responsibilities for their populations.  Some of the common myths are that “payers don’t care about PRO evidence, PROs only matter if they make it to the label, and that PROs should only be collected in Phase IV.” The facts are that not all payers are alike. Some pay a lot of attention to PRO evidence. Payers will consider all data from pivotal trials, whether or not it is on the package insert, and coverage decisions will be made on pivotal trials, so waiting until Phase IV to collect PROs would be too late.

Q: What are the common barriers in generating high-quality, patient-centric RWE?

AJ: I think the common barriers to generating RWE and patient-centric RWE are very similar; researchers must ensure that the data exists, that the data is capturing the relevant underlying medical concept, and that it is generated in a way that limits bias and confounding. Traditional RWD sources, like claims and EHRs, often have limited patient-centric data. This is a challenge for researchers attempting to incorporate this information into their studies. However, groups like Friends of Cancer Research and data providers like Monsenso are working to ensure this information is being collected. Once it is collected, it is essential to validate that these data and algorithms are actually measuring what we are intending to measure. Finally, researchers must be cognizant of bias and confounding and control for this as much as possible through study design and analytic methods. 

CL: Adding to Ashley’s points, I think data privacy and security, patients’ burden of contributing to research, and standardized methodology to analysis and interpretation are common barriers. It may seem like a no-brainer to ensure that patient data is managed in a secure way, but a recent study showed that almost a third of health apps out there collect patient data without privacy policy, and about one in five data transmissions occurred on insecure communication protocols. Furthermore, as patients are already suffering from their disease or conditions, contributing to research could add to their burden, which is why data capture platforms should be designed in a way that is easy-to-use and that provides valuable insights to patients. Finally, there is a lack of standardization in analysis and interpretation—which is why companies like Aetion are important to ensure that critical questions are answered, data sets are relevant, and standards are followed to derive and present meaningful insights that will inform decision-making.

Q: How can biopharma generate high-quality, patient-centric RWE for decision-makers? 

AJ: In addition to addressing the common barriers mentioned above, we think it is important to follow a principled approach to study design and execution. The main reasons why decision-makers like regulators and HTAs/payers dismiss RWE are due to deficient data selection and insufficient methodology. Following principled epidemiologic methods of selecting fit-for-purpose data, avoiding common methodological mistakes, and ensuring the protocol and results are clearly communicated are essential to ensuring the decision-makers trust the evidence. This planning and execution of RWE studies is not easy; it takes forethought. Biopharma manufacturers should be considering RWE at every stage of the product lifecycle, and proactively planning for how RWE studies will be incorporated into each product’s launch. 

Q. What is the cost-benefit for biopharma of generating patient-centric RWE? 

CL: Relative to the costs of bringing a new drug to market – which could go up to billions of dollars and take over a decade, with limited success ratesthe costs associated with collecting patient-centric RWE is insignificant. In return, patient-centric evidence could provide significant savings and valuable insights as early as possible to ensure that new drugs are truly driven by patients’ unmet needs, that they impact outcomes that matter to patients, and, ultimately, that they have the greatest chance of reaching the market and making a meaningful difference to patients. 

AJ: RWE can provide value for biopharma organizations across the product lifecycle—from eliminating costs typically incurred during clinical trials to accelerating time to market. Using a validated RWE platform can take this a step further, allowing companies to run more efficient, credible studies and reach insights faster than they could with traditional line programming. By ensuring patient-centric outcomes are collected in clinical data sources, then incorporating patient-centric RWE across drug development and commercialization programs, biopharma organizations can unlock insights that deliver value not only for their company but for patients as well. 

Q: Lastly, for our readers who are not familiar with Monsenso, Looi can you kindly tell a little more about what Monsenso does? 

CL: of course, Monsenso is a digital health company that enables patient-centric care and research. We’re a spinout from the IT University of Copenhagen based on the groundbreaking research of Professor Lars Kessing and Dr. Mads Frost on bipolar disorder and depression. We were founded in 2013 and have been listed on Nasdaq First North in Denmark since 2020. Our solution enables pharma companies to collect self-reported and device-generated data directly from patients in a simple, scalable, secure, and cost-effective way. Our cloud-based platform connects patients and investigators via an app and a web portal, respectively, to collect data in real-time across clinical development, post-market studies, and clinical practice to inform decision-making. Our platform can integrate with wearable devices and sensors, and combine with other RWD sources to provide a more holistic view of the impact of a drug on patients’ lives.